ALTIMMUNE, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum
ALTIMMUNE, INC. (ALT) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum of 1.59% for the 12-month period ending 2016-12-31, per its 10-K filed 2017-03-14.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum · last filed 2017-03-14
- ALTIMMUNE, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2016 was 1.59%, a 29.33% decline from fiscal 2015.
- ALTIMMUNE, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2015 was 2.25%, a 0.00% change from fiscal 2014.
- ALTIMMUNE, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2014 was 2.25%, a 18.42% increase from fiscal 2013.
- ALTIMMUNE, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2013 was 1.90%, a 61.02% increase from fiscal 2012.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 12 month |
|---|---|
| 2016-12-31 | 1.59% 10-K · filed 2017-03-14 |
| 2015-12-31 | 2.25% 10-K · filed 2017-03-14 |
| 2014-12-31 | 2.25% 10-K · filed 2017-03-14 |
| 2013-12-31 | 1.90% 10-K · filed 2016-03-11 |
| 2012-12-31 | 1.18% 10-K · filed 2015-03-11 |
| 2011-12-31 | 2.79% 10-K · filed 2014-03-11 |
| 2010-12-31 | 3.20% 10-K · filed 2013-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |